The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
Open accessAbstract
The analgesic properties of the synthetic cannabinoid WIN55,212‐2 were investigated in a model of neuropathic pain. In male Wistar rats, bilateral hind limb withdrawal thresholds to cold, mechanical and noxious thermal stimuli were measured. Following this, unilateral L5 spinal nerve ligation was performed. Seven days later, sensory thresholds were reassessed and the development of allodynia to cold and mechanical stimuli and hyperalgesia to a noxious thermal stimulus confirmed. The effect of WIN55,212‐2 (0.1 – 5.0 mg kg−1, i.p.) on the signs of neuropathy was then determined; there was a dose related reversal of all three signs of painful neuropathy at doses which did not generally alter sensory thresholds in the contralateral unligated limb. This effect was prevented by co‐administration of the CB 1 receptor antagonist SR141716a, but not by co‐administration of the CB 2 receptor antagonist SR144528, suggesting this action of WIN55,212‐2 is mediated via the CB 1 receptor. Administration of SR141716a alone had no affect on the observed allodynia and hyperalgesia, which does not support the concept of an endogenous analgesic tone. These data indicate that cannabinoids may have therapeutic potential in neuropathic pain, and that this effect is mediated through the CB 1 receptor. British Journal of Pharmacology (2001) 133, 586–594; doi:10.1038/sj.bjp.0704110
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“A second cannabinoid receptor (CB2), with 44% sequence homology to CB1, was identi®ed and cloned in 1993 (Munro et al., 1993) and was found to be predominantly expressed by cells of the immune system.”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Ho Kim, S., & Mo Chung, J. (1992) · Pain · doi:10.1016/0304-3959(92)90041-9 · Cited by 3,069 · cited 2×
“A direct comparison of various features of these three models of neuropathic pain has been reported (Kim et al., 1997).”
BackgroundMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“A further breakthrough in the elucidation of cannabinoid pharmacology came in 1988 with the discovery of a cannabinoid receptor in rat brain (CB1, Devane et al., 1988).”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Seltzer, Z., Dubner, R., & Shir, Y. (1990) · Pain · doi:10.1016/0304-3959(90)91074-s · Cited by 1,847
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Herzberg, U., Eliav, E., Bennett, G. J., & Kopin, I. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13308-5 · Cited by 307
Cited by
Millan, M. J. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00009-6 · Cited by 3,035
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…studies indicate that anandamide and cannabinoid ligands are also very effective against chronic pain of both neuropathic (Herzberg et al., 1997; Bridges et al., 2001; Fox et al., 2001; Guindon and Beaulieu, 2006) and inflammatory origin (Tsou et al., 1996; Richardson et al., 1998a,b,c; Li et…”
BackgroundCannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors
Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J., Rubino, T., Michalski, C. W., Marsicano, G., Monory, K., et al. (2007) · Nature Neuroscience · doi:10.1038/nn1916 · Cited by 571
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
SVIZENSKA, I., DUBOVY, P., & SULCOVA, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.010 · Cited by 457
Guindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Ständer, S., Schmelz, M., Metze, D., Luger, T., & Rukwied, R. (2005) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2005.01.007 · Cited by 298
Manzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., & Vaughan, C. W. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706510 · Cited by 287
Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy
Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., & Atkinson, J. H. (2015) · The Journal of Pain · doi:10.1016/j.jpain.2015.03.008 · Cited by 276
Mitrirattanakul, S., Ramakul, N., Guerrero, A. V., Matsuka, Y., Ono, T., Iwase, H., Mackie, K., Faull, K. F., & Spigelman, I. (2006) · Pain · doi:10.1016/j.pain.2006.06.016 · Cited by 207
“Our findings provide an explanation for the persistent effectiveness of peripherally administered CB1R agonists in alleviating the painful symptoms of peripheral neuropathy (Bridges et al., 2001; Fox et al., 2001; Costa et al., 2004).”
BackgroundThe endogenous cannabinoid system and its role in nociceptive behavior
Cravatt, B. F., & Lichtman, A. H. (2004) · Journal of Neurobiology · doi:10.1002/neu.20080 · Cited by 203
Lim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195
“E-mail address: jmao@partners.org (J. Mao). et al., 1997, 1998a,b; Mao et al., 2000; Bridges et al., 2001; Fox et al., 2001).”
Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain
Wallace, V. C. J., Blackbeard, J., Segerdahl, A. R., Hasnie, F., Pheby, T., McMahon, S. B., & Rice, A. S. C. (2007) · Brain · doi:10.1093/brain/awm195 · Cited by 176
Self-citationToth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012) · Pain · doi:10.1016/j.pain.2012.06.024 · Cited by 174
“Although scientific research has repeatedly demonstrated beneficial effects of cannabinoids upon NeP behaviours [3,9,21], clinical data for cannabinoids in the treatment of chronic pain conditions are conflicting.”
BackgroundAnalgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain
Jhaveri, M. D., Richardson, D., Kendall, D. A., Barrett, D. A., & Chapman, V. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3326-06.2006 · Cited by 159
“CB1 receptor-mediated antinociception has been widely described in neuropathic rats (Herzberg et al., 1997; Mao et al., 2000; Bridges et al., 2001; Fox et al., 2001; Monhemius et al., 2001; Helyes et al., 2003; Lim et al., 2003; Scott et al., 2004; Pascual et al., 2005; Sagar et al., 2005).”
BackgroundRahn, E. J., Makriyannis, A., & Hohmann, A. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707333 · Cited by 146
Hasnie, F. S., Breuer, J., Parker, S., Wallace, V., Blackbeard, J., Lever, I., Kinchington, P. R., Dickenson, A. H., Pheby, T., & Rice, A. S. C. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.029 · Cited by 144
Wallace, V. C. J., Cottrell, D. F., Brophy, P. J., & Fleetwood-Walker, S. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03221.2003 · Cited by 134
Walczak, J.-S., Pichette, V., Leblond, F., Desbiens, K., & Beaulieu, P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.02.010 · Cited by 133
A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats
Pascual, D., Goicoechea, C., Suardíaz, M., & Martín, M. I. (2005) · Pain · doi:10.1016/j.pain.2005.07.008 · Cited by 117
LaBuda, C. J., & Little, P. J. (2005) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.11.008 · Cited by 108
Costa, B., Siniscalco, D., Trovato, A. E., Comelli, F., Sotgiu, M. L., Colleoni, M., Maione, S., Rossi, F., & Giagnoni, G. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706798 · Cited by 99
Experience with the Synthetic Cannabinoid Nabilone in Chronic Noncancer Pain
Berlach, D. M., Shir, Y., & Ware, M. A. (2006) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00085.x · Cited by 96
Guindon, J., & Beaulieu, P. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.12.002 · Cited by 90
Actions of N-arachidonyl-glycine in a rat neuropathic pain model
Vuong, L. A. Q., Mitchell, V. A., & Vaughan, C. W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.004 · Cited by 89
Costa, B., Colleoni, M., Conti, S., Trovato, A. E., Bianchi, M., Sotgiu, M. L., & Giagnoni, G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705587 · Cited by 89
Dyson, A., Peacock, M., Chen, A., Courade, J.-P., Yaqoob, M., Groarke, A., Brain, C., Loong, Y., & Fox, A. (2005) · Pain · doi:10.1016/j.pain.2005.03.037 · Cited by 85
Bestard, J. A., & Toth, C. C. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2010.00427.x · Cited by 76
Are oral cannabinoids safe and effective in refractory neuropathic pain?
Attal, N., Brasseur, L., Guirimand, D., Clermond‐Gnamien, S., Atlami, S., & Bouhassira, D. (2004) · European Journal of Pain · doi:10.1016/s1090-3801(03)00084-3 · Cited by 74
Wallace, V. C. J., Segerdahl, A. R., Lambert, D. M., Vandevoorde, S., Blackbeard, J., Pheby, T., Hasnie, F., & Rice, A. S. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707326 · Cited by 66
“These effects, together with similar findings in models of inflammatory pain, are mediated via both cannabinoid CB1 and CB2 receptors (Bridges et al., 2001; Fox et al., 2001; Farquhar-Smith et al., 2002).”
BackgroundMethodInfluentialSelf-citationDe Vry, J., Denzer, D., Reissmueller, E., Eijckenboom, M., Heil, M., Meier, H., & Mauler, F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062836 · Cited by 63
Sain, N. M. H., Liang, A., Kane, S. A., & Urban, M. O. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.004 · Cited by 51
Wang, S., Lim, G., Mao, J., Sung, B., Yang, L., & Mao, J. (2007) · Pain · doi:10.1016/j.pain.2006.12.019 · Cited by 46
Williams, J., Haller, V. L., Stevens, D. L., & Welch, S. P. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.035 · Cited by 45
Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models
Mitchell, V. A., Greenwood, R., Jayamanne, A., & Vaughan, C. W. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04692.x · Cited by 43
La Rana, G., Russo, R., D'Agostino, G., Sasso, O., Raso, G. M., Iacono, A., Meli, R., Piomelli, D., & Calignano, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.021 · Cited by 42
“Furthermore, even repeated treatments with WIN 55,212-2 led to similar anti-hyperalgesic and anti-allodynic effects, confirming previous reports on the anti-hyperalgesic effect of acute treatment of WIN 55,212-2 (Herzberg et al., 1997; Bridges et al., 2001).”
ResultAntinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury
Hama, A., & Sagen, J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.002 · Cited by 40
Leichsenring, A., Andriske, M., Bäcker, I., Stichel, C. C., & Lübbert, H. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0386-4 · Cited by 39
Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain
Liu, C., & Walker, J. M. (2006) · Journal of Neurophysiology · doi:10.1152/jn.00498.2006 · Cited by 37
“B: pretreatment with selective CB1 antagonists, SR141716A (1 mg/kg) or AM251 (1 mg/kg), but not the CB2 antagonist, SR144528 (1 mg/kg), blocked the ability of WIN 55,212–2 to inhibit noxious heat-evoked responses of the neurons in CCI animals, suggesting a CB1 receptor-mediated effect.”
BackgroundResultInfluentialHama (2009) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2008.04.0049 · Cited by 32
Chapman, V. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00125-3 · Cited by 25
Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain
Guindon, J., Desroches, J., Dani, M., & Beaulieu, P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.060 · Cited by 24
Bujalska, M. (2008) · Pharmacology · doi:10.1159/000156485 · Cited by 20
Metadata
- Authors
- Bridges, D., Ahmad, K., & Rice, A. S. C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2001-06
- Volume
- 133
- Issue
- 4
- Pages
- 586-594
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2029775732
- Cited by
- 221
- References
- 11
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.